SWOG9321-STANDARD DOSE VS MYELOABLATIVE THERAPY FOR PREVIOUSLY UNTREATED MYELOMA

SWOG9321-标准剂量与清髓疗法治疗先前未经治疗的骨髓瘤

• 批准号: 6282269
• 负责人: GERMAN BELTRAN
• 金额: $ 1.97万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1999-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6282269
• 关键词: antineoplastics; clinical research; dosage; drug screening /evaluation; human subject; human therapy evaluation; multiple myeloma; neoplasm /cancer chemotherapy; neoplasm /cancer remission /regression

The general objectives of this study are to perform a randomized trial, in newly diagnosed patients with symptomatic multiple myeloma (MM), of standard therapy versus myeloablative therapy, in order to examine whether the greater tumor cytoreduction effected by intensive therapy and manifested by higher incidence of complete remission translates into extended overall survival and progression-free survival.

本研究的总体目标是进行随机试验， 在新诊断的症状性多发性骨髓瘤（MM）患者中， 标准疗法 对比清髓性治疗， 强化治疗是否能使肿瘤细胞减少， 表现为完全缓解的发生率较高， 延长总生存期和无进展生存期。